Interethnic comparisons of important pharmacology genes using SNP databases: Potential application to drug regulatory assessments

Pharmacogenomics

Volumn 11, Issue 8, 2010, Pages 1077-1094

  Chen, Jieming ^a   Teo, Yik Ying ^b   Toh, Dorothy S L ^c   Sung, Cynthia ^c  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c HEALTH SCIENCES AUTHORITY   (Singapore)

Author keywords

drug metabolism; haplotype diversity; interethnic variation; pharmacogenomics; population divergence; population pharmacogenetics; SNP; transporter

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALCOHOL DEHYDROGENASE; ALCOHOL DEHYDROGENASE 1A; ALCOHOL DEHYDROGENASE 1B; ALCOHOL DEHYDROGENASE 1C; AROMATIC HYDROCARBON RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BRCA1 PROTEIN; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE 2 RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNH2; REDUCED FOLATE CARRIER; SODIUM CHANNEL NAV1.5; SULFOTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ARTICLE; CAUCASIAN; CHINESE; CHROMOSOME SIZE; DECISION TREE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC DATABASE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HAPLOTYPE MAP; HUMAN; INDIAN; MALAYSIA; PHARMACOGENOMICS; POPULATION GENETICS; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DATABASES, GENETIC; DRUG AND NARCOTIC CONTROL; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; INDIA; MALAYSIA; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SINGAPORE;

EID: 77955590562     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.79     Document Type: Article

References (44)

1. Teo YY, Sim X, Ong RTH et al.: Singapore Genome Variation Project: A haploytpe map of three South-East Asian populations. Genome Res. 19(11), 2154-2162 (2009).
2. Hapmap Consortium: A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005).
3. Sangkuhl K, Berlin DS, Altman RB, Klein TE: PharmGKB: understanding the effects of individual genetic variants. Drug Metab. Rev. 40(4), 539-551 (2008).
4. Wright S: The genetical structure of populations. Ann. Eugen. 15, 323-354 (1951).
5. st. Nat. Rev. Genet. 10(9), 639-650 (2009).
6. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
7. Link E, Parish S, Armitage J et al.: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
8. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D: Effciency and power in genetic association studies. Nat. Genet. 37(11), 1217-1223 (2005).
9. Teo YY, Small KS: A novel method for haplotype clustering and visualization. Genet. Epidemiol. 34(1), 34-41 (2009).
10. Conrad DF, Jakobsson M, Coop G et al.: A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat. Genet. 38(11), 1251-1260 (2006).
11. Jakobsson M, Scholz SW, Scheet P et al.: Genotype, haplotype and copy-number variation in worldwide human populations. Nature 451(7181), 998-1003 (2008).
12. Wright S: Variability Within and Among Natural Populations. University of Chicago, Chicago, IL, USA, 4 (1978).
13. Tham LS, Goh BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80(4), 346-355 (2006).
14. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007).
15. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14(13), 1745-1751 (2005).
16. Lee SC, Ng SS, Oldenburg J et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79(3), 197-205 (2006).
17. Schwarz UI, Ritchie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999-1008 (2008).
18. Relling MV: Polymorphic drug metabolism. Clin. Pharm. 8(12), 852-863 (1989).
19. Kivisto K T, Niemi M: Infuence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24(2), 239-247 (2007).
20. Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73(6), 554-565 (2003). (Pubitemid 37249126)
21. Ho RH, Choi L, Lee W et al.: Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet. Genomics 17(8), 647-656 (2007).
22. Bosma PJ, Chowdhury JR, Bakker C et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333(18), 1171-1175 (1995).
23. Koiwai O, Nishizawa M, Hasada K et al.: Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP- glucuronosyltransferase. Hum. Mol. Genet. 4(7), 1183-1186 (1995).
24. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60(24), 6921-6926 (2000).
25. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
26. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2(1), 43-47 (2002).
27. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10(15), 5151-5159 (2004).
28. Sai K, Saeki M, Saito Y et al.: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75(6), 501-515 (2004).
29. Toffoli G, Cecchin E, Gasparini G et al.: Genotype-driven Phase I study of irinotecan administered in combination with fuorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(5), 866-871 (2009).
30. Minami H, Sai K, Saeki M et al.: Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics 17(7), 497-504 (2007).
31. Onoue M, Terada T, Kobayashi M et al.: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol. 14(2), 136-142 (2009).
32. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95(14), 8170-8174 (1998).
33. Jada SR, Lim R, Wong CI et al.: Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 98(9), 1461-1467 (2007).
34. Johnson AD, Kavousi M, Smith AV et al.: Genome-wide association meta-analysis for total serum bilirubin levels. Hum. Mol. Genet. 18(14), 2700-2710 (2009).
35. Sanna S, Busonero F, Maschio A et al.: Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum. Mol. Genet. 18(14), 2711-2718 (2009).
36. Pang GS, Wang J, Wang Z, Lee CG: Predicting potentially functional SNPs in drug-response genes. Pharmacogenomics 10(4), 639-653 (2009).
37. Clark AG, Hubisz MJ, Bustamante CD, Williamson SH, Nielsen R: Ascertainment bias in studies of human genome-wide polymorphism. Genome Res. 15(11), 1496-1502 (2005).
38. Wall JD, Cox MP, Mendez FL, Woerner A, Severson T, Hammer MF: A novel DNA sequence database for analyzing human demographic history. Genome Res. 18(8), 1354-1361 (2008).
39. Miller RD, Phillips MS, Jo I et al.: High-density single-nucleotide polymorphism maps of the human genome. Genomics 86(2), 117-126 (2005).
40. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
41. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
42. National Offce of Public Health Genomics: 10 years of Public Health Genomics at CDC 1997-2007 (2007).
43. The HUGO Pan-Asian SNP Consortium: Mapping human genetic diversity in Asia. Science 326(5959), 1541-1545 (2009).
44. Indian Genome Variation Consortium: Genetic landscape of the people of India: a canvas for disease gene exploration. J. Genet. 87(1), 3-20 (2008).